{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:03:09Z","timestamp":1794535389434,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Von Hippel-Lindau (VHL) disease is a hereditary tumor predisposition syndrome characterized by benign and malignant tumors affecting multiple organ systems. Standard treatment primarily involves surgical resection and tumor ablation, which can lead to progressive organ dysfunction. Belzutifan, an oral hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor, has emerged as a novel therapeutic option for VHL-associated tumors. However, data on its efficacy and safety outside of clinical trials remain limited. This study evaluates the outcomes of off-label belzutifan treatment in patients with advanced VHL-related organ manifestations, where standard therapeutic options were limited or contraindicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on eight patients with genetically or clinically confirmed VHL disease treated with belzutifan at a specialized VHL center in Germany. The median treatment duration was 16.4 months (range: 3.6\u201326 months). Disease stabilization was achieved in all patients, with a partial response observed in three cases. Tumor progression was noted in two patients, involving the emergence of new lesions, but no progression occurred in the primary target lesions, prompting treatment initiation. Belzutifan demonstrated tumor control across multiple organ systems, reducing the need for surgical interventions. The most common adverse event was anemia, occurring in all patients, with three requiring erythropoiesis-stimulating agents or dose reductions. Mild leukocytopenia and transient liver enzyme elevations were observed but did not require treatment modifications. Other adverse effects included infections, which were managed with temporary treatment interruptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Belzutifan represents a promising treatment option for VHL disease, particularly in patients for whom surgery carries significant risks. The therapy demonstrated effective tumor control and delayed disease progression in most cases. However, anemia remains a key side effect requiring close monitoring and management. Larger, long-term studies are needed to further assess the efficacy and safety of belzutifan in VHL patients and to refine treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15192-8","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:14:55Z","timestamp":1761959695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Belzutifan for patients with\u00a0Von Hippel-Lindau\u00a0(VHL) disease-associated heterogeneous tumors \u2013 a retrospective single center analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Kilian","family":"Rhein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fruzsina","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Ganner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Astheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Julia","family":"Gizaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannik","family":"Laich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula Annette","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Helge","family":"Klingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Neumann-Haefelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"Issue 14","key":"15192_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/jnci\/90.14.1039","volume":"90","author":"N Lindor","year":"1998","unstructured":"Lindor N, Greene MH. Concise handbook of family cancer syndromes | JNCI: journal of the National cancer Institute | Oxford academic. J Natl Cancer Inst. 1998;90(Issue 14):1039\u201371.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"15192_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1399-0004.2009.01281.x","volume":"77","author":"MLM Poulsen","year":"2010","unstructured":"Poulsen MLM, Budtz-J\u00f8rgensen E, Bisgaard ML. Surveillance in von Hippel-Lindau disease (vHL). Clin Genet. 2010;77(1):49\u201359.","journal-title":"Clin Genet"},{"key":"15192_CR3","doi-asserted-by":"publisher","unstructured":"Zhou B, Wang J, Liu S, Peng X, Hong B, Zhou J et al. Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients. Front Oncol. 2019 Oct 9 [cited 2024 Oct 22];9. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2019.01037\/full","DOI":"10.3389\/fonc.2019.01037\/full"},{"key":"15192_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fped.2018.00016","volume":"6","author":"E Kim","year":"2018","unstructured":"Kim E, Zschiedrich S. Renal cell carcinoma in von Hippel\u2013Lindau Disease\u2014From tumor genetics to novel therapeutic strategies. Front Pediatr. 2018;6:16.","journal-title":"Front Pediatr"},{"issue":"12","key":"15192_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1159\/000369362","volume":"37","author":"S Schmid","year":"2014","unstructured":"Schmid S, Gillessen S, Binet I, Br\u00e4ndle M, Engeler D, Greiner J, et al. Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat. 2014;37(12):761\u201371.","journal-title":"Oncol Res Treat"},{"issue":"10","key":"15192_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00381-020-04712-5","volume":"36","author":"JH Klingler","year":"2020","unstructured":"Klingler JH, Gl\u00e4sker S, Bausch B, Urbach H, Krauss T, Jilg CA, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020;36(10):2537\u201352.","journal-title":"Childs Nerv Syst"},{"issue":"9","key":"15192_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrneph.2013.144","volume":"9","author":"B Bausch","year":"2013","unstructured":"Bausch B, Jilg C, Gl\u00e4sker S, Vortmeyer A, L\u00fctzen N, Anton A, et al. Renal cancer in von Hippel\u2013Lindau disease and related syndromes. Nat Rev Nephrol. 2013;9(9):529\u201338.","journal-title":"Nat Rev Nephrol"},{"key":"15192_CR8","unstructured":"Saitta A, Nicolai M, Giovannini A, Mariotti C. Juxtapapillary Retinal Capillary Hemangioma: New Therapeutic Strategies. Med Hypothesis Discov Innov Ophthalmol. 2014 Autumn;3(3):71."},{"key":"15192_CR9","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.2147\/OTT.S190753","volume":"13","author":"S Gl\u00e4sker","year":"2020","unstructured":"Gl\u00e4sker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau disease: current challenges and future prospects. OncoTargets Ther. 2020;13:5669\u201390.","journal-title":"OncoTargets Ther"},{"key":"15192_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2014","unstructured":"Gossage L, Eisen T, Maher E. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2014;15:55\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"15192_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the \u03b2-domain of the von Hippel\u2013Lindau protein. Nat Cell Biol. 2000;2(7):423\u20137.","journal-title":"Nat Cell Biol"},{"key":"15192_CR12","doi-asserted-by":"crossref","unstructured":"Chen W fang, Hill H, Christie A, Kim M, Holloman E, Pav\u00eda-Jim\u00e9nez A et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112\u20137.","DOI":"10.1038\/nature19796"},{"issue":"22","key":"15192_CR13","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. N Engl J Med. 2021;385(22):2036\u201346.","journal-title":"N Engl J Med"},{"issue":"22","key":"15192_CR14","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","volume":"28","author":"J Fallah","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA approval summary: Belzutifan for von Hippel-Lindau Disease\u2013Associated tumors. Clin Cancer Res. 2022;28(22):4843\u20138.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"15192_CR15","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.34896","volume":"129","author":"AB Daniels","year":"2023","unstructured":"Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the international VHL surveillance guidelines consortium and VHL alliance. Cancer. 2023;129(19):2927\u201340.","journal-title":"Cancer"},{"issue":"7","key":"15192_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"15192_CR17","doi-asserted-by":"crossref","unstructured":"Saeed Z, Tasleem A, Asthagiri A, Schiff D, Jo J. Fatal intracranial hemorrhage with Belzutifan in von Hippel-Lindau Disease\u2013Associated hemangioblastoma: A case report. JCO Precis Oncol. 2023;(7):e2300066.","DOI":"10.1200\/PO.23.00066"},{"issue":"2","key":"15192_CR18","first-page":"228","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"3","key":"15192_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ncponc0451","volume":"3","author":"J Bohlius","year":"2006","unstructured":"Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and Recombinant human erythropoietin\u2013an updated overview. Nat Clin Pract Oncol. 2006;3(3):152\u201364.","journal-title":"Nat Clin Pract Oncol"},{"issue":"8749","key":"15192_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","volume":"337","author":"HP Neumann","year":"1991","unstructured":"Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet Lond Engl. 1991;337(8749):1052\u20134.","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"15192_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced Renal-Cell carcinoma. N Engl J Med. 2024;391(8):710\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"15192_CR22","doi-asserted-by":"publisher","first-page":"104538","DOI":"10.1016\/j.ejmg.2022.104538","volume":"65","author":"M Louise","year":"2022","unstructured":"Louise M, Binderup M, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, M\u00f8ller HU, et al. Von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022;65(8):104538.","journal-title":"Eur J Med Genet"},{"issue":"6","key":"15192_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. Von Hippel\u2013Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011;19(6):617\u201323.","journal-title":"Eur J Hum Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15192-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15192-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:15:05Z","timestamp":1761959705000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15192-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15192"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15192-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients participating in our study, which was approved by the responsible ethics committee of the University of Freiburg (approval number 79\/20). This study involving human participants was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1686"}}